This content is from: Premium
Hedge Funds Are Holding Their Breath on This Biopharma IPO
Several prominent hedge funds disclosed sizable stakes in PepGen, which went public earlier this month.
The folks at PepGen certainly showed some courage earlier this month when they chose to proceed with their initial public offering.On May 5, the development-stage biopharma company sold nine million shares at $12 a pop. It had hoped to offer 7.2 million shares between $13 and $15 a share, according
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.